Partnership TTW-KWF-LSH: info session
Technology for Oncology II
Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Background and Partnership Partners

- First Partnership programme ‘Technology for Oncology’ in 2015
- Overwhelming interest
In the first partnership 11 promising projects were granted.

One of the main priorities of KWF Kankerbestrijding is to fast-track the translation of scientific results to daily clinical practice.

We are happy to participate in this Technology for Oncology II partnership program;
  • Technological development becomes more and more a priority within our portfolio.
  • In this way we create awareness for our own *KWF Programme Research & Implementation* as suitable option for follow-up studies.
Technology for Oncology II: budget and scope

Programme budget: 5,8 M EUR

Scope of the projects:

- Development of technology with a significant and identifiable impact on one or more of the mission goals of KWF Kankerbestrijding: less cancer, more cure and a better quality of life.

- The potential to utilize the obtained knowledge and results in oncology prevention, diagnosis, treatment and care should be the primary focus

- Technological development is patient focused and targets a specific problem (future) cancer patients are facing
Technology for Oncology II: objectives

Objectives:

- (New) **collaborations** and technology transfer between Dutch Technical Universities or research groups with proven technical expertise and other research institutes

- Participation of, and collaboration with, **industry** in cancer-related technology development

- **Technology** that can be used to improve prevention, diagnosis and/or treatment of cancer, including quality of life.
Technology for Oncology II: not eligible for funding

- Technology development not directly targeting application in oncology
- Technology development with research purposes/use only
- Solely product development and/or testing (no clear technical scientific challenge)
- Clinical trials, as defined by cohort studies or phase I/II studies and beyond;
- Experimental research as defined by the PPP definition
- Research must be executed without any involvement of the tobacco industry in any manner whatsoever.
Technology for Oncology II: requirements PPP allowance

- Project activities should consist of fundamental and/or industrial research as defined by PPP allowance (per workpackage + financial planning!)
- At least **15% co-funding**, including cash entry fee by industrial partners
- Industrial partners (for-profit!) contribute **cash AND in-kind**
- Co-funding universities and non-industrial Partners, not counting towards co-funding criterium

Your contact for all questions related to PPP allowance: Laila el Aziz!
Technology for Oncology II: requirements PPP allowance

- Duration of the project max. 4 years
- Project Agreement, optie 1
- Fit in the roadmaps Top Sector LSH and societal challenge ‘Health Care’

Your contact for all questions related to PPP allowance: Laila el Aziz!
Technology for Oncology II: Criteria consortium

- At least two (2) distinct research institutes
- Proven technical and oncological expertise
- Users: industrial parties, non-industrial parties, experts, societal/patient organizations
- At least 4 users, of which two users should be an industrial partner
- After award: User committee
Technology for Oncology II: applications

- Main (1x) and Co applicant (>1x)
- Resubmission
- Funding elsewhere:
  - Please state in the proposal
- Excluded are:
  - NWA-ORC,
  - Open Technology Programme (OTP),
  - Perspectief Programme,
  - KWF Kankerbestrijding Programme Research & Implementation,
  - Top Sector LSH Match Call
Technology for Oncology II: applications

Applications have to be submitted via ISAAC. Please familiarize yourself timely!

Full Proposal = application form* + required appendices (4 PDFs)
- Letters of support (1 combined PDF)
- Data management plan
- Financial Overview (2 sheets)
- Declaration main applicant (signed)
Technology for Oncology II: Assessment criteria

- **Scientific Quality**
  - Important and urgent problem in oncology
  - Innovative elements
  - Deliverables and time schedule

- **Utilization (prospects), including relevance for the patient**
  - Implementation perspective
  - Utilization plan in line with scope programme
  - Cooperation between researchers and users

- **Relevance Patient**
  - Improve quality of life
  - Improve quality of care
  - Participation patient organisation

The questions for reviewers published on website with call for proposals
### Time lines: assessment procedure

<table>
<thead>
<tr>
<th>Event</th>
<th>Date/Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deadline full proposals (ISAAC)</td>
<td>9 May 2019; 14:00h CEST</td>
</tr>
<tr>
<td>APPLICANT: Revised version</td>
<td>2nd half May 2019 (1 week)</td>
</tr>
<tr>
<td>Assessment by (international) referees</td>
<td>May - August 2019</td>
</tr>
<tr>
<td>APPLICANT: Rebuttal</td>
<td>1st half September 2019 (1 week)</td>
</tr>
<tr>
<td>Advice programme committee to TTW Board</td>
<td>October 2019</td>
</tr>
<tr>
<td>Decision by TTW Board*</td>
<td>November 2019</td>
</tr>
<tr>
<td>Final start date for projects</td>
<td>May 2020 (6 months after award)</td>
</tr>
</tbody>
</table>

*NWO Grant rules 2017 will apply to all awarded project*
Contact

- Program Officers
  Marjolein van Dalen m.vandalen@nwo.nl +31 30 6001 234
  Wieke Haakma w.haakma@nwo.nl +31 30 6001 296

- Legal Advisor
  Behnam Sobhani b.sobhani@nwo.nl +31 30 6001 282

- Website
  www.nwo.nl/ttw-aes
Questions?